"raf Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely-related serine-threonine kinases that were originally identified as the cellular homologs of the retrovirus-derived V-RAF KINASES. They are MAP kinase kinase kinases that play important roles in SIGNAL TRANSDUCTION.
| Descriptor ID |
D048490
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.842 D12.644.360.400.842 D12.776.476.400.842 D12.776.624.664.700.204
|
| Concept/Terms |
raf Kinases- raf Kinases
- Kinases, raf
- raf Proto-Oncogene Proteins
- Proto-Oncogene Proteins, raf
- raf Proto Oncogene Proteins
- raf MAP Kinase Kinase Kinases
- raf Serine-Theonine Protein Kinases
- raf Serine Theonine Protein Kinases
- Proto-Oncogene Proteins raf
- Proteins raf, Proto-Oncogene
- Proto Oncogene Proteins raf
mil-raf Protein Kinases- mil-raf Protein Kinases
- Kinases, mil-raf Protein
- Protein Kinases, mil-raf
- mil raf Protein Kinases
- MIL-RAF Proteins
- MIL RAF Proteins
|
Below are MeSH descriptors whose meaning is more general than "raf Kinases".
Below are MeSH descriptors whose meaning is more specific than "raf Kinases".
This graph shows the total number of publications written about "raf Kinases" by people in this website by year, and whether "raf Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 5 | 5 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "raf Kinases" by people in Profiles.
-
DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. Cell Rep. 2019 12 10; 29(11):3448-3459.e6.
-
Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. J Natl Cancer Inst. 2017 11 01; 109(11).
-
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med. 2016 Feb 09; 14:46.
-
Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs. 2015 Sep; 26(8):835-42.
-
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife. 2015 Aug 18; 4.
-
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):E1724-33.
-
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2.
-
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014 Sep 01; 74(17):4845-4852.
-
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
-
PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep. 2013 Oct 31; 5(2):314-22.